Imitrex Indication:

For the treatment of migraine attacks with or without aura in adults

Imitrex Mechanism Of Action:

Imitrex stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Imitrex also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve.

Imitrex Drug Interactions:

Not Available

Imitrex Food Interactions:

Not Available

Imitrex Generic Name:

Synonyms:

  • Sumatriptan Succinate
  • Sumatriptanum [Inn-Latin]
  • NP101

Drug Type:

Small Molecule; Approved; Investigational

Absorption:

Approximately 15%

Toxicity (Overdose):

Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.

Protein Binding:

14%-21%

Biotransformation:

Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme.

Half Life:

2.5 hours

Dosage Forms of Imitrex:

Liquid Subcutaneous
Tablet Oral
Spray Nasal
Patch, extended release Transdermal

Chemical IUPAC Name:

1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide

Organisms Affected:

Humans and other mammals

Imitrex to general, pharmacology

General, pharmacology..